Outlook Therapeutics (OTLK) has released an update to notify the public and investors about the unregistered sales of equity securities.
The information regarding the Private Placement and Syntone Private Placement has been integrated into this report, indicating that the sale of Shares, Warrants, and their underlying Common Stock, as well as Syntone Shares and Syntone Warrants, will proceed without registration under the Securities Act. This is based on exemptions for non-public offerings and sales to accredited investors under federal and state laws. The involved parties have provided necessary representations in their respective purchase agreements, and this report does not constitute an offer to sell or a solicitation of an offer to buy any securities.
For further insights into OTLK stock, check out TipRanks’ Stock Analysis page.
